NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 2012
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
3
Data completeness
5/8 — Partial
QSYMIA (phentermine and topiramate) by Teva is cytochrome p450 3a4 inducers [moa]. Approved for hepatic impairment. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QSYMIA is an oral extended-release capsule combining phentermine and topiramate, approved in 2012 for weight management in patients with hepatic impairment. It functions as a CYP3A4 inducer to modulate appetite and metabolic pathways. The combination leverages phentermine's sympathomimetic effects with topiramate's anticonvulsant properties to enhance satiety and reduce caloric intake.
Peak3.1 years to LOE
Product is at peak lifecycle maturity with high competitive pressure (8/10), indicating mature commercial infrastructure but intensifying margin defense challenges for sales and marketing teams.
Mechanism of Action
Cytochrome P450 3A4 Inducers
Clinical Trials (3)
Phase IV Study of Qsymia in Obese Patients
Started Sep 2021
232 enrolled
Obesity
Qsymia as an Adjunct to Surgical Therapy in the Superobese
Started Dec 2014
25 enrolled
ObesityMetabolic SurgeryWeight Loss+1 more
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
Started Aug 2014
51 enrolled
Obesity
Worked on QSYMIA at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.